Loading...

WOCKPHARMA Wockhardt Ltd Product Launches Announcement

Wckh

WCKP

Wockhardt Ltd

(WOCKPHARMA)

2026 Announcement

Investor call transcript

Investor Presentation

Regulatory Compliance

New Product Launch

Monitoring Agency Report

Senior Management Appointment

Audited Results

Fundraising Proposal

Equity fundraising plan

Board Meeting Intimation

SEBI Regulation 30 disclosure

Regulatory Confirmation

Regulatory Recommendation

Trading window closure

Special Transfer Window

ESG Rating Disclosure

QIP proceeds utilization

Q3 results release

Board meeting outcome

Unaudited Standalone Results

New Product Launch

ESG Rating Disclosure

Regulatory Compliance

Marketing Authorisation Filing

ESG Rating Disclosure

Regulatory update

Regulatory Compliance

Subsidiary incorporation

Regulatory disclosure response

FDA regulatory approval

Regulatory disclosure

Postal Ballot Notice

Volume Movement Response

Monitoring Report Issued

Positive Q2 Results

Management Change

Financial Results

Board Meeting Outcome

Compliance Certificate

New Drug Application

Newspaper Publication

Miqnaf Clinical Study

ESG Rating Update

Credit Rating Upgrade

Share Allotment

Monitoring Agency Report

Q1 Results Announcement

Special Share Lodgement

Medical Journal Publication

AGM Announcement

Compliance Certificate

Strategic Realignment

Earnings Call Transcript

Investor Presentation

Investor Presentation

Financial Results

Management Changes

Annual Compliance Report

Monitoring Agency Report

Compliance Certificate

New Subsidiary Formed

Successful Treatment

Share Allotment

Funds Utilization Update

Monitoring Agency Report

Q3 Financial Results

New Antibiotic Success

Compliance Certificate

New Drug Efficacy

New Antibiotic Approval

Successful Liver Transplant

No Fund Deviation

QIP Utilization Report

Financial Results Q2

Equity Shares Allotment

Investor Meeting

Investor Meeting

Investor Presentation

Volume Movement Clarified

Compliance Certificate

New Antibiotic Launch

Management Change

Lifetime Achievement Award

New Drug Success

New Drug Success

Innovator Award Received

Regulatory Fines Imposed

Allegations Denied

Redemption of Debenture

Earnings Results

Funds Utilization Confirmation

Monitoring Agency Report

Financial Results & Appoint...

Compliance Certificate Subm...

Management Change

WOCKHARDT LTD. Press Release

Successful Use of Antibiotic

Management Change

Appointment of Auditors

Financial Update

Antibiotic trial update

Annual Compliance Report Su...

Credit Rating Announcement

Funds Utilization Confirmation

Monitoring Report

Credit rating change by ICR...

Certificate Issuance

Compliance Certificate Rece...

Compliance Certificate

Tenure Completion

Allotment of Equity Shares

Clinical Success Announcement

Investor Presentation

Financial Results

Revised Outcome Submission

Allotment of ESOP/ESPS

Certificate Submission

IEPF Share Transfer

Phase 3 Pneumonia Study

Financial Results

Equity Allotment

Compliance Certificate Subm...

Credit Rating Revision

Financial Statements

Voluntary Delisting

Equity Offerings

Layoffs, Labor disputes

Financial Statements, Earni...

Financial Statements

Other Situations

Other Situations

Credit Downgrade

Related party transactions

Financial Results Announcement

Regulatory Compliance

Investor Meetings

External Links:

Data:

Wockhardt secures regulatory marketing authorization for ZAYNICH (Zidebactam/Cefepime) in India, with NDA/MAA filings and US FDA priority designations in progress.

AI Assistant

Wockhardt Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.